[In patients hospitalized for COVID-19, does dexamethasone reduce 28-days mortality compared to standard treatment?]

Lanthier, L; Mayette, M; Huard, G; Plourde, M-É; Cauchon, M

[In patients hospitalized for COVID-19, does dexamethasone reduce 28-days mortality compared to standard treatment?] / Chez les sujets hospitalisés pour COVID-19, est-ce que la dexaméthasone diminue la mortalité à 28jours comparativement au traitement standard ?

Lanthier, L; Mayette, M; Huard, G; Plourde, M-É; Cauchon, M.

Lanthier L; Département de médecine spécialisé, service de médecine interne générale, Université de Sherbrooke, Sherbrooke, QC, Canada. Electronic address: luc.lanthier@usherbrooke.ca.
Mayette M; Département de médecine spécialisé, service de médecine interne générale, Université de Sherbrooke, Sherbrooke, QC, Canada.
Huard G; Département de médecine spécialisé, service de médecine interne générale, Université de Sherbrooke, Sherbrooke, QC, Canada.
Plourde MÉ; Département de médecine nucléaire et radiobiologie, service de radio-oncologie, Université de Sherbrooke, Sherbrooke, QC, Canada.
Cauchon M; Département de médecine familiale et de médecine d'urgence, Université Laval, Québec, QC, Canada.

Rev Med Interne ; 41(11): 790-791, 2020 11.

Article in French | MEDLINE | ID: covidwho-882755

Subject(s)

Anti-Inflammatory Agents/therapeutic use; COVID-19 Drug Treatment; COVID-19/mortality; Dexamethasone/therapeutic use; Aged; Female; Hospitalization; Humans; Male; Randomized Controlled Trials as Topic; Time Factors

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Dexamethasone / COVID-19 / COVID-19 Drug Treatment / Anti-Inflammatory Agents Type of study: Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male Language: French Journal: Rev Med Interne Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google